Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma.

Description: CD137 (4-1BB), a member of the tumor necrosis factor receptor superfamily, is a type I transmembrane glycoprotein expressed on the cell surface of activated splenic T cells and thymocytes. The functions of CD137 in T lymphocytes include regulating activation, proliferation and apoptosis. CD137 and CD28 are costimulatory molecules of T cell activation. Costimulatory molecules are important in initiating anti-tumor immune responses. CD137 plays an important role in regulating T-cell-dependent immune responses. Expression of CD137 correlates negatively with lymphocyte proliferation and positively with the degree of activation-induced cell death caused by mitogen overstimulation. In monocytes, CD137 induces activation, promotes adherence and prolongs survival. The LOB12.3 antibody is an agonistic antibody that has been shown to stimulate 4-1BB signaling and delay tumor growthin vivowhen administered in combination with immune checkpoint inhibitors.

Description: CD137 (4-1BB), a member of the tumor necrosis factor receptor superfamily, is a type I transmembrane glycoprotein expressed on the cell surface of activated splenic T cells and thymocytes. The functions of CD137 in T lymphocytes include regulating activation, proliferation and apoptosis. CD137 and CD28 are costimulatory molecules of T cell activation. Costimulatory molecules are important in initiating anti-tumor immune responses. CD137 plays an important role in regulating T-cell-dependent immune responses. Expression of CD137 correlates negatively with lymphocyte proliferation and positively with the degree of activation-induced cell death caused by mitogen overstimulation. In monocytes, CD137 induces activation, promotes adherence and prolongs survival. The LOB12.3 antibody is an agonistic antibody that has been shown to stimulate 4-1BB signaling and delay tumor growthin vivowhen administered in combination with immune checkpoint inhibitors.

Description: CD137 (4-1BB), a member of the tumor necrosis factor receptor superfamily, is a type I transmembrane glycoprotein expressed on the cell surface of activated splenic T cells and thymocytes. The functions of CD137 in T lymphocytes include regulating activation, proliferation and apoptosis. CD137 and CD28 are costimulatory molecules of T cell activation. Costimulatory molecules are important in initiating anti-tumor immune responses. CD137 plays an important role in regulating T-cell-dependent immune responses. Expression of CD137 correlates negatively with lymphocyte proliferation and positively with the degree of activation-induced cell death caused by mitogen overstimulation. In monocytes, CD137 induces activation, promotes adherence and prolongs survival. The LOB12.3 antibody is an agonistic antibody that has been shown to stimulate 4-1BB signaling and delay tumor growthin vivowhen administered in combination with immune checkpoint inhibitors.

Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma.

Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma.

Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma.

Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma.

Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma.

Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma.

Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma.

Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma.

Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma.

Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma.

Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma.

Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma.

Description: A Rabbit polyclonal antibody against Pig Ubiquitin Cross Reactive Protein (UCRP)